BioSpace News Archive

‒ Institutional Review Boards (IRBs) Approve Amended Phase 2 Protocol with Newly Enrolled Patients Receiving a 2.5 mg Dose, 1.5 mg Dose, or Placebo ‒ ‒ Company Continues to Expect Completion of Enrollment in Q3:20 and Intends to Follow All Patients for Bone Mineral Density and Biomarker (BMD) Data After Six Months of Treatment ‒ ‒ Biomarker Data from the Higher Dose Groups Expected in Early Q1:21 with Full Six-month BMD Data Expected in Early Q2:21 ‒ BOSTON and JERUSALEM, July 07, 202

Kronos Bio, Inc., dedicated to targeting oncogenic transcription factors and associated transcriptional regulatory networks, today announced the appointment of Jennifer Nicholson, M.H.A., to the newly created position of Vice President, Regulatory Affairs. Ms. Nicholson joins the company with nearly 20 years of experience in regulatory affairs, with a focus on oncology across all stages of develop

Data Published in eBioMedicine Validates Novel Scientific Approach That Disarms Bacterial Defenses to Treat or Prevent Life-threatening Infections Approach effectively degrades bacterial protective shields to enable immune or antibiotic intervention COLUMBUS, Ohio--( BUSINESS WIRE )-- Clarametyx Biosciences Inc ., (“Clarametyx”) a preclinical stage biotechnology company developing targeted, immune-enabling biologic therapies to counter persistent in

International Foundation for Gastrointestinal Disorders (IFFGD) recognizes three young investigators for their contributions to the advancement of science for chronic GI disorders

Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that new data from the ongoing Phase 1b study of KSI-301, its novel anti-VEGF antibody biopolymer conjugate, will be presented at the upcoming America

Apellis Pharmaceuticals Inc., a global biopharmaceutical company pioneering targeted C3 therapies, announced that it completed enrollment in the Phase 3 DERBY and OAKS studies investigating intravitreal pegcetacoplan, a targeted C3 therapy, for the treatment of geographic atrophy secondary to age-related macular degeneration.

Publications Demonstrate the Ability of the PRS Component of riskScore® to Accurately Stratify Breast Cancer Risk in Women Both With and Without Pathogenic Mutations

Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that it has initiated a Phase 1 study to investigate a novel immunotherapy approach for patients with COVID-19.

Nasus Pharma announced data from a preclinical collaboration with the University of Virginia School of Medicine that demonstrated TaffiX®, the Company’s innovative nasal powder inhaler that effectively blocks viruses from reaching nasal mucosa, was able to block more than 99% of SARS-CoV-2 viruses.

Ionis Pharmaceuticals, Inc. announced that it will host a live webcast on Tuesday, July 14th at 10:00 a.m. Eastern Time to review its neurology franchise.